Quick Answer Box
- What the case is: A federal mass tort (MDL 3037) against Horizon Therapeutics, now owned by Amgen, alleging Tepezza caused permanent hearing loss and tinnitus without adequate label warnings
- Who qualifies: Patients who received one or more Tepezza infusions and subsequently experienced hearing loss, tinnitus, autophony, or related auditory injury, generally confirmed by audiological testing
- What it may be worth: Individual payouts are estimated between $150,000 and $500,000+ depending on injury severity, with severe permanent hearing loss cases at the higher end of current projections
Case Snapshot
| Detail | Information |
|---|---|
| Case Name | In re: Tepezza Marketing, Sales Practices and Products Liability Litigation |
| MDL Number | MDL 3037 |
| Court | U.S. District Court, Northern District of Illinois, Eastern Division |
| Presiding Judge | Hon. Thomas M. Durkin |
| Consolidation Date | February 6, 2023 |
| Defendant | Horizon Therapeutics (acquired by Amgen, October 2023) |
| Case Status | Active MDL, bellwether discovery and trial preparation ongoing as of 2026 |
| Settlement Fund | No global settlement announced as of Q1 2026; individual negotiations ongoing |
| Approximate Claimants | 3,000+ cases pending in MDL as of early 2026 |
The Tepezza Lawsuit Update Every Claimant Needs in 2026
The Tepezza lawsuit update for 2026 reflects a mass tort in active forward motion, with thousands of claimants positioned inside MDL 3037 and bellwether trials shaping what individual cases are ultimately worth.
This is not a settled matter with a fixed fund to draw from. It is a live federal docket before Judge Thomas M. Durkin in the Northern District of Illinois, where the outcome of early trials will determine whether Amgen, now the parent company of original defendant Horizon Therapeutics, moves toward a global resolution or fights claim by claim.
That distinction matters. Claimants who understand the MDL process will make better decisions about timing, attorney selection, and settlement expectations than those who assume this works like a consumer refund program.
The drug at the center of this litigation is teprotumumab-trbw, marketed as Tepezza, the first FDA-approved treatment for thyroid eye disease. The allegation is that Horizon knew about ototoxicity risks and failed to warn patients or prescribing physicians adequately.
What Is the Tepezza Lawsuit 2026 Status?
The Tepezza lawsuit in 2026 is an active federal multi-district litigation with no global settlement in place and bellwether trials serving as the primary pressure mechanism on both sides.
MDL 3037 was formally established on February 6, 2023, when the Judicial Panel on Multidistrict Litigation transferred cases from multiple federal districts to the Northern District of Illinois. Since then, the docket has grown to more than 3,000 filed cases, with additional claims continuing to enter the litigation.
Judge Durkin has overseen discovery disputes, expert witness scheduling, and the bellwether selection process. The court's schedule through 2025 and into 2026 has focused on identifying which cases are factually representative enough to serve as trial proxies for the broader plaintiff population.
Key 2026 Procedural Milestones:
- Bellwether pool selection from MDL docket is complete
- Expert discovery in designated bellwether cases is substantially advanced
- First bellwether trials expected to be scheduled or underway in 2026
- Global settlement talks, while not publicly confirmed, are a standard feature of this MDL stage
*Attorney Insight: Attorneys handling these claims note that the period immediately surrounding bellwether trials is historically when defendants' settlement offers increase materially, particularly if the first trials produce plaintiff-favorable verdicts.*
What Is the Tepezza Class Action Lawsuit?
The Tepezza class action lawsuit is more accurately described as a pharmaceutical mass tort consolidated into an MDL, not a traditional opt-in class action with a shared settlement fund divided among all claimants.
The distinction is significant for claimants. In a class action, every class member receives a pro-rata share of a fixed fund, often a few hundred dollars. In a mass tort MDL, each plaintiff maintains an individual claim. Damages are assessed based on that specific plaintiff's injury, medical history, and impact on quality of life.
This means a Tepezza plaintiff with documented permanent sensorineural hearing loss and audiologist testimony has a fundamentally different damages profile than a plaintiff who experienced temporary tinnitus.
Mass Tort MDL vs. Traditional Class Action:
| Feature | Mass Tort MDL | Class Action |
|---|---|---|
| Individual claim | Yes | No (shared recovery) |
| Damages based on individual injury | Yes | No |
| Opt-out required | No | Sometimes |
| Client retains own attorney | Yes | Lead counsel represents class |
| Payout varies by injury | Yes | Generally uniform |
| Bellwether trials | Yes | Rare |
*Attorney Insight: Attorneys handling pharmaceutical mass torts consistently advise clients that preserving individual case value requires retaining counsel early, before any global settlement framework is established.*
Tepezza MDL Update 2026: Where the Litigation Stands
The MDL 3037 update for 2026 centers on three developments: the bellwether trial pipeline, Amgen's posture as the successor defendant, and the ongoing accumulation of scientific evidence linking teprotumumab to cochlear damage.
Amgen acquired Horizon Therapeutics in October 2023 for approximately $27.8 billion. That acquisition transferred Horizon's litigation liabilities. Amgen is now the effective defendant in MDL 3037, and plaintiffs' counsel have characterized this as a defendant with significantly deeper resources than the original Horizon entity.
Judge Durkin's management of discovery has included rulings on privilege disputes and expert qualification standards that will shape how audiological injury evidence is presented at trial. These rulings are part of the public docket in MDL 3037.
2026 MDL Status Indicators:
- Docket: MDL 3037, N.D. Ill.
- Presiding judge: Hon. Thomas M. Durkin
- Defendant now: Amgen Inc. (successor to Horizon Therapeutics)
- Current phase: Bellwether trial preparation and expert witness phase
- Global settlement: Not announced as of Q1 2026
*Attorney Insight: Attorneys in mass torts with newly acquired defendant corporations note that the acquiring company's financial exposure often produces different settlement calculations than those of the original smaller defendant.*
Litigation Watch: MDL 3037 is in its most consequential phase of 2026. Bellwether trial outcomes will set the de facto value range for individual Tepezza claims. Claimants who have not yet retained counsel face narrowing windows to participate in early settlement negotiations.
The Horizon Therapeutics Lawsuit and Amgen's Liability
The Horizon Therapeutics lawsuit originated with the company's alleged failure to disclose ototoxicity risks in Tepezza's clinical development and post-approval marketing.
Clinical trial data, according to the plaintiffs, showed rates of hearing impairment that were not adequately captured in original FDA labeling. The FDA updated Tepezza's prescribing information in 2023 to include a strengthened warning about hearing loss and tinnitus. Plaintiffs argue that warning came years too late for thousands of patients already treated.
Horizon generated approximately $1.66 billion in Tepezza revenue in 2022 alone, making the drug its largest commercial product before the Amgen acquisition. Plaintiffs' counsel have used that revenue figure to contextualize arguments about the commercial incentive to minimize risk disclosures.
Amgen's acquisition of Horizon did not include indemnification provisions that would shift the litigation liability back to Horizon's former principals, making Amgen the responsible party for any judgment or settlement in MDL 3037.
*Attorney Insight: Attorneys evaluating pharmaceutical liability cases consistently flag FDA label update timing as one of the most critical elements of a failure-to-warn claim, because the update itself serves as an implicit acknowledgment of the risk.*
Tepezza Hearing Loss Lawsuit: The Core Injury Claim
The tepezza hearing loss lawsuit is grounded in the allegation that teprotumumab causes sensorineural hearing loss, an injury to the inner ear's hair cells or auditory nerve that is, in many cases, irreversible.
Unlike conductive hearing loss, which can sometimes be treated with surgery or hearing aids, sensorineural hearing loss affects how the brain receives sound signals from the cochlea. Patients have reported difficulty distinguishing speech, loss of high-frequency hearing, and in more severe cases, total deafness in one or both ears.
Published peer-reviewed studies have documented this connection. A 2021 study in the journal Thyroid found that 65% of patients in one cohort experienced some degree of hearing change during or after Tepezza treatment. The rate of clinically significant loss was higher than what Horizon disclosed in its original labeling.
Documented Tepezza Hearing Injuries:
- Sensorineural hearing loss (partial or total)
- High-frequency hearing loss
- Tinnitus (persistent ringing, buzzing, or hissing)
- Autophony (hearing one's own voice abnormally amplified)
- Eustachian tube dysfunction
- Hyperacusis (abnormal sound sensitivity)
*Attorney Insight: Attorneys handling these claims note that objective audiological documentation, specifically pre- and post-treatment audiograms, is the single strongest evidentiary asset a plaintiff can bring to negotiations.*
Tepezza Tinnitus Lawsuit: A Distinct Injury Category
The tepezza tinnitus lawsuit represents a separate, large subset of the overall MDL, one where plaintiffs experience phantom sound perception rather than measurable hearing threshold shifts.
Tinnitus is not trivial. For patients with severe, persistent tinnitus, the condition disrupts sleep, concentration, and psychological health. In damages terms, however, tinnitus claims without an accompanying objective audiological finding are generally assigned lower settlement values than claims involving documented threshold shifts on an audiogram.
Plaintiffs' attorneys in MDL 3037 have argued that tinnitus caused by Tepezza meets the threshold for compensable injury under products liability law because it is a direct and foreseeable consequence of teprotumumab's mechanism of action, specifically its blockade of IGF-1R receptors that are present in cochlear tissue.
Tinnitus Claim Factors That Affect Value:
| Factor | Effect on Claim Value |
|---|---|
| Severity rating (1 to 10 scale documented by physician) | Higher severity, higher value |
| Duration (ongoing vs. resolved) | Ongoing tinnitus increases value |
| Objective audiogram findings alongside tinnitus | Significantly increases value |
| Impact on employment or daily function | Increases non-economic damages |
| Pre-existing tinnitus or hearing conditions | May reduce or complicate value |
*Attorney Insight: Attorneys note that tinnitus-only claimants without supporting audiological data tend to be categorized in lower settlement tiers, but strong expert testimony on cochlear IGF-1R disruption can elevate these claims substantially.*
Tepezza Side Effects Lawsuit: Beyond Hearing
The Tepezza side effects lawsuit encompasses injuries beyond hearing loss, though the auditory injury claims represent the dominant and most litigated category within MDL 3037.
Other reported adverse effects connected to Tepezza include hyperglycemia, inflammatory bowel disease exacerbation, and muscle spasms. These were disclosed, to varying degrees, in Tepezza's original labeling. The hearing injury claims differ because plaintiffs argue they were not adequately disclosed and because the FDA's 2023 label revision implicitly acknowledged the gap.
Claims involving non-auditory side effects without a hearing injury component are present in the MDL but are less numerous and carry different causation challenges. The FDA's 2023 warning update was specific to hearing and tinnitus, giving those claims a stronger regulatory anchor than non-auditory claims.
Tepezza Adverse Events in MDL 3037 by Category:
- Primary: Sensorineural hearing loss, tinnitus, autophony
- Secondary: Hyperglycemia, glucose metabolism disruption
- Tertiary: Inflammatory bowel disease, muscle cramps, alopecia
The overwhelming majority of active MDL 3037 plaintiffs are pursuing auditory injury claims.
*Attorney Insight: Attorneys evaluating Tepezza cases for non-auditory injuries note that without a parallel FDA warning update covering those conditions, causation is harder to establish and defendants have more room to contest specific attribution.*
Litigation Watch: The scientific record, specifically the peer-reviewed cochlear IGF-1R research and the FDA's 2023 label update, forms the evidentiary backbone of virtually every active Tepezza claim in MDL 3037. Claimants without audiological documentation face a materially harder path regardless of their symptom history.
Tepezza Permanent Hearing Loss Claim: Highest-Value Cases
The tepezza permanent hearing loss claim is the highest-value category within MDL 3037, with damages projections that reflect the lifetime economic and quality-of-life consequences of irreversible auditory injury.
Permanent sensorineural hearing loss affects employment, relationships, safety awareness, and mental health. Expert economists retained by plaintiffs' firms have modeled lifetime income loss for professional-class plaintiffs with hearing-dependent careers, producing damages figures that significantly exceed projections for less severe injuries.
Current projections from attorneys familiar with MDL 3037 negotiations suggest permanent, bilateral hearing loss cases may settle in ranges between $350,000 and $500,000 or more, depending on plaintiff age, professional impact, and the strength of causation documentation.
Permanent Hearing Loss Claim Components:
- Medical expenses (hearing aids, cochlear implant evaluation, audiological care)
- Lost wages and reduced earning capacity
- Pain and suffering (non-economic damages)
- Loss of enjoyment of life
- Future medical monitoring costs
- Potential punitive damages if Horizon's conduct meets the applicable standard
*Attorney Insight: Attorneys in pharmaceutical hearing loss cases note that plaintiff age at time of treatment is one of the most significant multipliers in economic damages models, because younger plaintiffs face more years of documented future impact.*
Who Qualifies for the Tepezza Lawsuit?
Who qualifies for the Tepezza lawsuit is determined by a combination of treatment history, documented injury, and applicable statute of limitations in the plaintiff's state.
The baseline eligibility criteria require that the claimant received at least one Tepezza (teprotumumab) infusion and subsequently developed a qualifying auditory injury. Most firms filing into MDL 3037 require some form of audiological documentation, though the absence of a formal audiogram does not automatically disqualify a potential plaintiff.
Tepezza Lawsuit Eligibility Checklist:
| Criterion | Required? |
|---|---|
| Received Tepezza infusion | Yes |
| Diagnosed with thyroid eye disease (Graves' ophthalmopathy) | Typically yes (this was the approved indication) |
| Experienced hearing loss, tinnitus, or auditory symptoms post-infusion | Yes |
| Audiological testing documenting hearing change | Strongly preferred |
| Symptoms within a medically plausible timeframe | Yes |
| No prior pending settlement related to same injury | Yes (no double recovery) |
The statute of limitations varies by state, typically two to three years from the date of injury discovery.
*Attorney Insight: Attorneys note that "date of discovery" is a legally defined concept, not simply the date symptoms appeared. Claimants who did not connect symptoms to Tepezza until later may still qualify under the discovery rule.*
Tepezza Lawsuit Eligibility Criteria: What Disqualifies a Claim?
The Tepezza lawsuit eligibility criteria exclude claimants who cannot establish a plausible causal connection between their Tepezza infusions and their auditory symptoms.
Pre-existing hearing loss documented before Tepezza treatment is the most common complicating factor. Defendants will rely on audiological records predating treatment to argue that any post-treatment hearing change falls within normal age-related variation. The stronger the pre-treatment audiological baseline, the more effectively plaintiffs can isolate Tepezza's contribution to the injury.
Age-related hearing loss, noise-induced hearing loss, ototoxic medications taken concurrently, and other prior ear conditions will all be scrutinized by defense medical experts.
Factors That May Weaken a Tepezza Claim:
- Documented hearing loss before first infusion
- Concurrent use of other known ototoxic drugs (aminoglycosides, cisplatin, loop diuretics)
- Failure to report auditory symptoms to treating physician during infusion course
- Delay of more than the applicable limitations period without tolling basis
- Inability to produce medical records documenting Tepezza treatment
*Attorney Insight: Attorneys handling these claims advise that concurrent ototoxic drug use does not automatically bar a claim, but it requires expert testimony to disaggregate contributions, which adds cost and risk to the litigation.*
Tepezza Bellwether Trial: What It Means for Your Claim
The Tepezza bellwether trial process is the mechanism by which both sides test their strongest and most representative cases before a jury, producing verdict data that drives global settlement negotiations.
In MDL practice, a "bellwether" is not a class-wide trial. It is a trial involving one or a small set of individual plaintiffs, selected because their facts represent a broad swath of the MDL population. If the plaintiff wins a $400,000 verdict in a bellwether case, that number becomes a reference point. If the defense wins, plaintiff settlement leverage decreases.
Judge Durkin has managed the bellwether selection process in MDL 3037 through a structured discovery protocol. Both sides submit candidate cases. The court selects a pool. Expert reports are exchanged and subject to Daubert challenges before any trial date is set.
Bellwether Trial Timeline (MDL 3037):
| Phase | Status |
|---|---|
| Bellwether pool selection | Substantially complete as of 2025 |
| Expert witness reports | Exchanged and subject to challenge |
| Daubert motions on expert opinions | Pending or resolved |
| First trial | Expected 2026 or per court schedule |
| Global settlement window | Typically opens after first verdict |
*Attorney Insight: Attorneys with MDL experience note that defendants frequently increase settlement offers by 30 to 60 percent in the 90 days following an adverse bellwether verdict, because the verdict validates the damages model for thousands of remaining claims.*
Litigation Watch: The bellwether trial results in MDL 3037 will function as the most important single variable in determining when and at what level Amgen agrees to a global resolution. Claimants should monitor those outcomes closely with counsel.
Tepezza Lawsuit Status: Current Docket Activity in 2026
The Tepezza lawsuit status as of 2026 reflects a litigation that has moved through early discovery and is now in its most critical evidentiary phase before trial.
The Northern District of Illinois docket for MDL 3037 shows ongoing motion practice on expert qualifications, case management orders establishing trial protocols, and continued intake of new plaintiff cases from across the country. Plaintiffs are represented by a Plaintiffs' Steering Committee (PSC) composed of experienced mass tort attorneys appointed by Judge Durkin.
The PSC coordinates discovery, expert retention, and settlement discussions on behalf of all MDL plaintiffs. Individual attorneys who have enrolled clients retain responsibility for their specific client's case strategy and communication.
MDL 3037 Active Docket Indicators (2026):
- Active case count: 3,000+ individual plaintiffs
- Jurisdiction: N.D. Ill., Eastern Division
- Coordinating judge: Hon. Thomas M. Durkin
- PSC: Appointed, operating as primary plaintiffs' leadership
- Discovery status: Expert phase substantially advanced
- Trial schedule: First bellwether trials on or approaching the court's 2026 calendar
*Attorney Insight: Attorneys following the MDL docket note that plaintiffs whose cases were filed early in the MDL may be positioned in the first bellwether pool, potentially reaching resolution before the broader claimant population.*
Tepezza Lawsuit Payout: How Damages Are Calculated
The Tepezza lawsuit payout is not a uniform figure. It is calculated on a plaintiff-by-plaintiff basis using a combination of economic losses, non-economic harm, and in some cases, punitive damages arguments.
Plaintiffs' counsel use damages models that include documented medical costs, projected future hearing care expenses, income loss tied to audiological impairment, and non-economic suffering. These models are presented through retained economic and audiological experts during trial or settlement mediation.
Tepezza Damages Categories:
| Category | Description | Estimated Range |
|---|---|---|
| Past medical expenses | Audiological care, hearing aids, treatments | $10,000 to $75,000+ |
| Future medical costs | Projected cochlear care, devices, monitoring | $20,000 to $150,000+ |
| Lost income | Career impact from hearing impairment | Varies widely by plaintiff |
| Pain and suffering | Physical and psychological impact | $50,000 to $300,000+ |
| Loss of enjoyment | Activities, relationships, quality of life | $25,000 to $150,000+ |
| Punitive damages | If misconduct threshold is met | Potentially additional |
Total projections for severe cases exceed $500,000 in some attorney models, though actual outcomes depend on trial results and negotiation.
*Attorney Insight: Attorneys note that plaintiff employment type and income documentation are among the most significant variables in economic damages calculations, making early financial record preservation critical.*
Tepezza Settlement Amount 2026: What the Numbers Suggest
The Tepezza settlement amount in 2026 is not yet established through a global fund, but individual negotiation and bellwether data are producing increasingly clear value ranges for different injury tiers.
No official announcement of a global settlement has been made as of Q1 2026. However, mass torts of this scale rarely announce global settlements until after at least one bellwether trial produces a verdict or until the court schedules an imminent trial date that creates sufficient pressure on the defense.
Based on publicly available information about comparable pharmaceutical hearing loss MDLs, analyst and attorney estimates for Tepezza cases break down as follows.
Projected Tepezza Settlement Tiers (2026 Estimates):
| Injury Tier | Description | Estimated Range |
|---|---|---|
| Tier 1 (Most Severe) | Bilateral permanent sensorineural hearing loss | $350,000 to $500,000+ |
| Tier 2 (Significant) | Unilateral permanent loss or significant tinnitus with audiogram | $150,000 to $350,000 |
| Tier 3 (Moderate) | Documented tinnitus, partial hearing reduction, resolved | $75,000 to $150,000 |
| Tier 4 (Least Severe) | Mild or temporary auditory symptoms, limited documentation | $25,000 to $75,000 |
These ranges are projections based on MDL posture and comparable litigation. They are not guaranteed outcomes.
*Attorney Insight: Attorneys caution that Tier 1 projections depend heavily on the outcome of the first bellwether trials. If defendants win those trials, global settlement offers across all tiers could decline significantly.*
How Much Is the Tepezza Lawsuit Worth?
How much the Tepezza lawsuit is worth depends on the individual plaintiff's injury severity, documentation quality, and how bellwether verdicts establish the damages framework.
The aggregate value of MDL 3037, assuming a global settlement involving 3,000 or more plaintiffs at mid-range values, could reach into the billions of dollars. For context, Amgen is a company with annual revenues exceeding $28 billion. Its capacity to fund a large resolution is not in question.
What remains unresolved is Amgen's willingness to accept that liability rather than litigate individual cases. If early bellwether trials produce plaintiff victories, that calculus changes rapidly.
Aggregate MDL Value Estimates:
- Low scenario (defense-favorable bellwethers): $500 million to $1 billion total
- Mid scenario (mixed verdicts): $1 billion to $2 billion total
- High scenario (plaintiff-favorable bellwethers): $2 billion+ total
These are modeling projections, not filed settlement amounts.
*Attorney Insight: Attorneys tracking pharmaceutical MDL settlements note that the per-claimant average in comparable auditory injury mass torts has ranged from $80,000 to $200,000 after attorneys' fees and expenses, though individual outcomes vary significantly from that average.*
Litigation Watch: The total value of MDL 3037 has not been determined. It will be set primarily by what juries decide in the first round of bellwether trials. That is why those trials are the most closely watched events in this litigation for 2026.
Tepezza Hearing Loss Settlement: What a Resolution Would Look Like
The Tepezza hearing loss settlement, when it arrives, will likely follow the structure used in other large pharmaceutical MDLs: a master settlement agreement with tiered compensation based on a point-based injury classification system.
In this model, every plaintiff's case is assigned points based on audiological severity, age, duration of treatment, and corroborating documentation. A per-point dollar value is then established, and individual payouts are calculated against that grid. This approach allows defendants to control total exposure while allowing plaintiffs' counsel to differentiate based on injury severity.
Before any master settlement is signed, each enrolled plaintiff must individually authorize participation. Claimants cannot be forced to accept a settlement against their will in a mass tort MDL.
Components of a Likely Tepezza Settlement Framework:
- Master settlement agreement between PSC and defendant
- Tiered compensation grid based on injury severity
- Individual plaintiff authorization required
- Attorney fee allocation (typically 33 to 40 percent of gross recovery)
- Claims administrator appointed by court to process payments
- Release of all future claims against Amgen and Horizon related to Tepezza
*Attorney Insight: Attorneys who have managed prior pharmaceutical MDL settlement distributions note that payment timelines from agreement to claimant receipt typically run six to eighteen months after the master agreement is signed.*
Tepezza Lawsuit Filing Deadline: Time Limits That Apply
The Tepezza lawsuit filing deadline is governed by the statute of limitations in each plaintiff's home state, and that deadline is not extended by the existence of MDL 3037.
Most states apply a two to three year limitations period for personal injury claims involving pharmaceutical drugs. The limitations clock typically begins when the plaintiff knew or reasonably should have known that their injury was connected to Tepezza, not necessarily when the injury first appeared.
The FDA's 2023 label update has been cited by some courts as a date by which patients and prescribers were on constructive notice of the hearing risk. Plaintiffs who experienced post-treatment hearing symptoms and delayed consulting an attorney may face limitations challenges depending on their state.
State Statute of Limitations (Selected Examples):
| State | Personal Injury Limit | Discovery Rule Available? |
|---|---|---|
| California | 2 years | Yes |
| Texas | 2 years | Yes |
| New York | 3 years | Yes |
| Florida | 2 years (revised 2023) | Yes |
| Illinois | 2 years | Yes |
| Pennsylvania | 2 years | Yes |
| Ohio | 2 years | Yes |
Bold callout: Filing after the statute of limitations has expired in your state will bar your claim entirely, regardless of how strong the underlying injury evidence is.
*Attorney Insight: Attorneys handling pharmaceutical cases strongly advise claimants to consult counsel before assuming their claim is time-barred. Tolling doctrines and the discovery rule have preserved claims that appeared untimely on the surface.*
Frequently Asked Questions
What is the current status of the Tepezza lawsuit in 2026?
MDL 3037 is active in the Northern District of Illinois before Judge Thomas M. Durkin.
No global settlement has been announced as of Q1 2026.
The litigation is in the bellwether trial preparation phase, with first trials expected on the 2026 court calendar.
How much money can I get from the Tepezza lawsuit?
Individual payout estimates range from approximately $25,000 for mild documented cases to $500,000 or more for permanent bilateral hearing loss.
Those projections are based on MDL posture and comparable pharmaceutical mass tort outcomes.
Final values will be shaped by bellwether trial results, which have not yet occurred.
Who is the defendant in the Tepezza lawsuit?
Amgen Inc. is the current effective defendant, having acquired Horizon Therapeutics in October 2023 for approximately $27.8 billion.
Horizon Therapeutics was the original developer and marketer of Tepezza.
Amgen assumed Horizon's litigation liabilities through the acquisition.
Do I need an audiogram to file a Tepezza claim?
An audiogram is not a strict legal prerequisite to file, but it is the strongest form of objective evidence available.
Claimants without audiological documentation face more difficulty establishing injury severity and causation.
Most attorneys handling MDL 3037 cases recommend obtaining current audiological testing as soon as possible.
Is there still time to file a Tepezza lawsuit in 2026?
Whether there is still time depends on your state's statute of limitations and when your symptoms became connected to Tepezza in your medical understanding.
Most states apply a two to three year window from date of discovery, not date of treatment.
Consulting a pharmaceutical mass tort attorney immediately is the only reliable way to determine whether your window is open.
What type of attorney handles Tepezza lawsuits?
Tepezza claims are handled by pharmaceutical mass tort attorneys and products liability lawyers with MDL experience.
These attorneys typically work on contingency, meaning no upfront cost to the claimant.
Firms actively enrolled in MDL 3037 are identified in the public docket of the Northern District of Illinois.
Closing
The Tepezza lawsuit update for 2026 is a story still being written inside Courtroom MDL 3037. Bellwether trials will set the real value of every pending claim. The closer those trials come, the more pressure builds on Amgen to reach a global resolution.
If you received Tepezza and now experience hearing loss or tinnitus, the time to evaluate your legal position is before that pressure releases. A pharmaceutical mass tort attorney can assess your audiological records, treatment timeline, and state-specific deadlines in an initial consultation. That step costs nothing and determines everything that follows.
